AustralieFrV1, Main, Exploration, bibRecord, 009679

Clinical trial : effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B

Identifieur interne : 009679 ( Main/Exploration ); précédent : 009678; suivant : 009680

Clinical trial : effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B

Auteurs : S. G. Lim [Singapour] ; P. Marcellin [France] ; N. Tassopoulos [Grèce] ; S. Hadziyannis [Grèce] ; T. T. Chang [Taïwan] ; M. Tong [États-Unis] ; W. Sievert [Australie] ; P. Hu [République populaire de Chine] ; S. Arterburn [États-Unis] ; C. L. Brosgart [États-Unis]

Source :

Alimentary pharmacology & therapeutics [ 0269-2813 ] ; 2007.

RBID : Pascal:08-0001717

Descripteurs français

Pascal (Inist)
- Essai clinique, Homme, Adéfovir, Traitement, Asiatique, Caucasoïde, Hépatite virale B, Antiviral.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Adefovir, Antiviral, Asiatic, Caucasoid, Clinical trial, Human, Treatment, Viral hepatitis B.

Abstract

Background Two-thirds of the 350 million people infected with chronic hepatitis B virus live in the Asia-Pacific region. Aim To compare the effects of adefovir dipivoxil therapy between Asian and Caucasian patients with chronic hepatitis B. Methods The safety and efficacy of 10 mg of adefovir dipivoxil was compared to placebo in 501 Asian (n = 259) or Caucasian (n = 242) HBeAg+ and HBeAg- chronic hepatitis B virus patients treated for 48 weeks in two randomized, double-blind, placebo-controlled studies. Results At week 48, histological improvement was observed in 60% and 56% of Caucasian and Asian patients, respectively. Change in serum hepatitis B virus DNA from baseline to week 48 for the adefovir dipivoxil-treated patients was -3.89 and -3.70 logic copies/mL in Caucasian and Asian patients, respectively, while 34 per cent of Caucasian patients and 39 per cent of Asian patients had undetectable serum hepatitis B virus DNA (<400 copies/mL) at week 48. The percentage of patients achieving alanine aminotransferase (ALT) normalization at week 48 was similar in both groups (Caucasian 64 per cent, Asian 63 per cent). No patients developed resistance through week 48. No differences in adverse events or grade 3 or 4 laboratory abnormalities were observed between groups. Conclusions There were no significant differences in treatment response between Asians and Caucasians. Adefovir dipivoxil was well tolerated and no resistance developed up to week 48 in both racial groups.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 003829
to stream PascalFrancis, to step Curation: 002809
to stream PascalFrancis, to step Checkpoint: 003A07
to stream Main, to step Merge: 00A119
to stream Main, to step Curation: 009679

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Clinical trial : effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B</title>
<author><name sortKey="Lim, S G" sort="Lim, S G" uniqKey="Lim S" first="S. G." last="Lim">S. G. Lim</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>National University Hospital</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
<wicri:noRegion>National University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marcellin, P" sort="Marcellin, P" uniqKey="Marcellin P" first="P." last="Marcellin">P. Marcellin</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Hospital Beaujon</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tassopoulos, N" sort="Tassopoulos, N" uniqKey="Tassopoulos N" first="N." last="Tassopoulos">N. Tassopoulos</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Hepatology, Metropolitan Hospital</s1>
<s2>Athens</s2>
<s3>GRC</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hadziyannis, S" sort="Hadziyannis, S" uniqKey="Hadziyannis S" first="S." last="Hadziyannis">S. Hadziyannis</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Henry Dunant Hospital, Liver Research Unit</s1>
<s2>Athens</s2>
<s3>GRC</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chang, T T" sort="Chang, T T" uniqKey="Chang T" first="T. T." last="Chang">T. T. Chang</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>National Cheng Kung University Hospital</s1>
<s2>Tainan</s2>
<s3>TWN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>National Cheng Kung University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tong, M" sort="Tong, M" uniqKey="Tong M" first="M." last="Tong">M. Tong</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Hunting ton Memorial Hospital</s1>
<s2>Pasadena, CA</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Hunting ton Memorial Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sievert, W" sort="Sievert, W" uniqKey="Sievert W" first="W." last="Sievert">W. Sievert</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Monash Medical Center</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Monash Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hu, P" sort="Hu, P" uniqKey="Hu P" first="P." last="Hu">P. Hu</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Peking Union Medical College Hospital</s1>
<s2>Peking</s2>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
<wicri:noRegion>Peking Union Medical College Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Arterburn, S" sort="Arterburn, S" uniqKey="Arterburn S" first="S." last="Arterburn">S. Arterburn</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Gilead Sciences, Inc</s1>
<s2>Foster City, CA</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Foster City, CA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brosgart, C L" sort="Brosgart, C L" uniqKey="Brosgart C" first="C. L." last="Brosgart">C. L. Brosgart</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Gilead Sciences, Inc</s1>
<s2>Foster City, CA</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Foster City, CA</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">08-0001717</idno>
<date when="2007">2007</date>
<idno type="stanalyst">PASCAL 08-0001717 INIST</idno>
<idno type="RBID">Pascal:08-0001717</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003829</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002809</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">003A07</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">003A07</idno>
<idno type="wicri:doubleKey">0269-2813:2007:Lim S:clinical:trial:effects</idno>
<idno type="wicri:Area/Main/Merge">00A119</idno>
<idno type="wicri:Area/Main/Curation">009679</idno>
<idno type="wicri:Area/Main/Exploration">009679</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Clinical trial : effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B</title>
<author><name sortKey="Lim, S G" sort="Lim, S G" uniqKey="Lim S" first="S. G." last="Lim">S. G. Lim</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>National University Hospital</s1>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Singapour</country>
<wicri:noRegion>National University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marcellin, P" sort="Marcellin, P" uniqKey="Marcellin P" first="P." last="Marcellin">P. Marcellin</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Hospital Beaujon</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>France</country>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Tassopoulos, N" sort="Tassopoulos, N" uniqKey="Tassopoulos N" first="N." last="Tassopoulos">N. Tassopoulos</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Hepatology, Metropolitan Hospital</s1>
<s2>Athens</s2>
<s3>GRC</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Hadziyannis, S" sort="Hadziyannis, S" uniqKey="Hadziyannis S" first="S." last="Hadziyannis">S. Hadziyannis</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Henry Dunant Hospital, Liver Research Unit</s1>
<s2>Athens</s2>
<s3>GRC</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Grèce</country>
<placeName><settlement type="city">Athènes</settlement>
<region nuts="2" type="region">Attique (région)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chang, T T" sort="Chang, T T" uniqKey="Chang T" first="T. T." last="Chang">T. T. Chang</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>National Cheng Kung University Hospital</s1>
<s2>Tainan</s2>
<s3>TWN</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Taïwan</country>
<wicri:noRegion>National Cheng Kung University Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tong, M" sort="Tong, M" uniqKey="Tong M" first="M." last="Tong">M. Tong</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Hunting ton Memorial Hospital</s1>
<s2>Pasadena, CA</s2>
<s3>USA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Hunting ton Memorial Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sievert, W" sort="Sievert, W" uniqKey="Sievert W" first="W." last="Sievert">W. Sievert</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Monash Medical Center</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>Monash Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hu, P" sort="Hu, P" uniqKey="Hu P" first="P." last="Hu">P. Hu</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Peking Union Medical College Hospital</s1>
<s2>Peking</s2>
<s3>CHN</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>République populaire de Chine</country>
<wicri:noRegion>Peking Union Medical College Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Arterburn, S" sort="Arterburn, S" uniqKey="Arterburn S" first="S." last="Arterburn">S. Arterburn</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Gilead Sciences, Inc</s1>
<s2>Foster City, CA</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Foster City, CA</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Brosgart, C L" sort="Brosgart, C L" uniqKey="Brosgart C" first="C. L." last="Brosgart">C. L. Brosgart</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Gilead Sciences, Inc</s1>
<s2>Foster City, CA</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Foster City, CA</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Alimentary pharmacology & therapeutics</title>
<title level="j" type="abbreviated">Aliment. pharmacol. ther.</title>
<idno type="ISSN">0269-2813</idno>
<imprint><date when="2007">2007</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Alimentary pharmacology & therapeutics</title>
<title level="j" type="abbreviated">Aliment. pharmacol. ther.</title>
<idno type="ISSN">0269-2813</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adefovir</term>
<term>Antiviral</term>
<term>Asiatic</term>
<term>Caucasoid</term>
<term>Clinical trial</term>
<term>Human</term>
<term>Treatment</term>
<term>Viral hepatitis B</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Essai clinique</term>
<term>Homme</term>
<term>Adéfovir</term>
<term>Traitement</term>
<term>Asiatique</term>
<term>Caucasoïde</term>
<term>Hépatite virale B</term>
<term>Antiviral</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background Two-thirds of the 350 million people infected with chronic hepatitis B virus live in the Asia-Pacific region. Aim To compare the effects of adefovir dipivoxil therapy between Asian and Caucasian patients with chronic hepatitis B. Methods The safety and efficacy of 10 mg of adefovir dipivoxil was compared to placebo in 501 Asian (n = 259) or Caucasian (n = 242) HBeAg+ and HBeAg- chronic hepatitis B virus patients treated for 48 weeks in two randomized, double-blind, placebo-controlled studies. Results At week 48, histological improvement was observed in 60% and 56% of Caucasian and Asian patients, respectively. Change in serum hepatitis B virus DNA from baseline to week 48 for the adefovir dipivoxil-treated patients was -3.89 and -3.70 logic copies/mL in Caucasian and Asian patients, respectively, while 34 per cent of Caucasian patients and 39 per cent of Asian patients had undetectable serum hepatitis B virus DNA (<400 copies/mL) at week 48. The percentage of patients achieving alanine aminotransferase (ALT) normalization at week 48 was similar in both groups (Caucasian 64 per cent, Asian 63 per cent). No patients developed resistance through week 48. No differences in adverse events or grade 3 or 4 laboratory abnormalities were observed between groups. Conclusions There were no significant differences in treatment response between Asians and Caucasians. Adefovir dipivoxil was well tolerated and no resistance developed up to week 48 in both racial groups.</div>
</front>
</TEI>
<affiliations><list><country><li>Australie</li>
<li>France</li>
<li>Grèce</li>
<li>République populaire de Chine</li>
<li>Singapour</li>
<li>Taïwan</li>
<li>États-Unis</li>
</country>
<region><li>Attique (région)</li>
<li>Île-de-France</li>
</region>
<settlement><li>Athènes</li>
<li>Paris</li>
</settlement>
</list>
<tree><country name="Singapour"><noRegion><name sortKey="Lim, S G" sort="Lim, S G" uniqKey="Lim S" first="S. G." last="Lim">S. G. Lim</name>
</noRegion>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Marcellin, P" sort="Marcellin, P" uniqKey="Marcellin P" first="P." last="Marcellin">P. Marcellin</name>
</region>
</country>
<country name="Grèce"><region name="Attique (région)"><name sortKey="Tassopoulos, N" sort="Tassopoulos, N" uniqKey="Tassopoulos N" first="N." last="Tassopoulos">N. Tassopoulos</name>
</region>
<name sortKey="Hadziyannis, S" sort="Hadziyannis, S" uniqKey="Hadziyannis S" first="S." last="Hadziyannis">S. Hadziyannis</name>
</country>
<country name="Taïwan"><noRegion><name sortKey="Chang, T T" sort="Chang, T T" uniqKey="Chang T" first="T. T." last="Chang">T. T. Chang</name>
</noRegion>
</country>
<country name="États-Unis"><noRegion><name sortKey="Tong, M" sort="Tong, M" uniqKey="Tong M" first="M." last="Tong">M. Tong</name>
</noRegion>
<name sortKey="Arterburn, S" sort="Arterburn, S" uniqKey="Arterburn S" first="S." last="Arterburn">S. Arterburn</name>
<name sortKey="Brosgart, C L" sort="Brosgart, C L" uniqKey="Brosgart C" first="C. L." last="Brosgart">C. L. Brosgart</name>
</country>
<country name="Australie"><noRegion><name sortKey="Sievert, W" sort="Sievert, W" uniqKey="Sievert W" first="W." last="Sievert">W. Sievert</name>
</noRegion>
</country>
<country name="République populaire de Chine"><noRegion><name sortKey="Hu, P" sort="Hu, P" uniqKey="Hu P" first="P." last="Hu">P. Hu</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 009679 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 009679 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:08-0001717
   |texte=   Clinical trial : effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Clinical trial : effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B

Clinical trial : effects of adefovir dipivoxil therapy in Asian and Caucasian patients with chronic hepatitis B

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri